Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785501 | 0.92 | VDR (0.49) | VDRPTGER3BCHECYSLTR2CYSLTR1 | |
| SCHEMBL6155609 | 0.90 | VDR (0.48) | VDRPTGER3BCHECYSLTR2CYSLTR1 | |
| SCHEMBL2107787 | 0.89 | VDR (0.40) | VDRPTGER3MRGPRX4BCHECYSLTR2 | |
| SCHEMBL6155503 | 0.89 | VDR (0.47) | VDRPTGER3CYSLTR2CYSLTR1 | |
| SCHEMBL6155463 | 0.86 | VDR (0.44) | VDRMRGPRX4BCHEMEN1KMT2A | |
| SCHEMBL2106608 | 0.84 | MRGPRX4 (0.42) | PTGER3MRGPRX4 | |
| SCHEMBL5968372 | 0.84 | PTGER3 (0.41) | PTGER3BCHECYSLTR2CYSLTR1MEN1 | |
| SCHEMBL6154985 | 0.84 | PTGER3 (0.35) | PTGER3MRGPRX4BCHECYSLTR2CYSLTR1 | |
| SCHEMBL6155571 | 0.81 | VDR (0.46) | VDRBCHECYSLTR2CYSLTR1 | |
| SCHEMBL6155242 | 0.78 | VDR (0.44) | VDRBCHECYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1686972-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | Galderma Research & Development, S.N.C. (FR) | 2006-08-09 | — | — | EP | claimed |
| WO-2005053666-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | WO | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| EP-2879656-B2 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2879649-B2 | DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT | OREAL (FR) | 2022-08-24 | — | — | EP | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-2879656-B1 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2019-05-29 | — | — | EP | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | VDR 4/4885PTGER3 1627/4885MRGPRX4 2961/4885 |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | CYP24A1, CYP2R1, VDR | VDR 3/4885PTGER3 832/4885MRGPRX4 1709/4885 |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | CYP19A1, CYP17A1, CYP51A1 | VDR 158/4885PTGER3 474/4885MRGPRX4 155/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | VDR 4085/4885PTGER3 4024/4885MRGPRX4 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.